BILAYER TABLET FORMULATIONS

Title:

BILAYER TABLET FORMULATIONS

Document Type and Number:

Japanese Patent JP2015110630

Kind Code:

A

Abstract:

PROBLEM TO BE SOLVED: To provide a method for producing bilayer tablet formulations, and to provide a therapeutic method of diseases or disorders associated with a sodium dependent glucose transporter inhibitor (SGLT2) activity using the bilayer tablet formulations.SOLUTION: The invention provides a bilayer tablet formulation which contains (1) a first layer which is metformin sustained release formulation and (2) a second layer which is SGLT2 inhibitor formulation, and may contain (3) a film coating which coats the first layer and the second layer suitably. Further in the bilayer tablet formulation, the SGLT2 inhibitor is Canagliflozin, Dapagliflozin, Dapagliflozin (S) propylene glycol hydroxide, or Dapagliflozin (R) propylene glycol hydroxide.

More Like This:

JP2009514830	Crystal transformation of N-ethyl-2,2-dichloro-1-methylcyclopropane-carboxamide-2- (2,6-dichloro-α, α, α-trifluoro-p-tolyl) hydrazone
JP3770947	4-MERCAPTOBENZOYLGUANIDINE DERIVATIVE
WO/2019/232740	PHARMACEUTICAL COMPOSITION FOR PREVENTING DIABETES AND USE THEREOF

Inventors:

ADMASSU ABEBE
KYLE MARTIN
JATIN M PATEL
DIVYAKANT DESAI
PETER TIMMINS

Application Number:

JP2015019633A

Publication Date:

June 18, 2015

Filing Date:

February 03, 2015

Export Citation:

Click for automatic bibliography generation Help

Assignee:

ASTRAZENECA AB
ASTRAZENECA UK LTD

International Classes:

A61K31/155; A61K9/28; A61K31/085; A61K31/381; A61K45/00; A61K47/04; A61K47/10; A61K47/12; A61K47/22; A61K47/32; A61K47/36; A61K47/38; A61P3/04; A61P3/06; A61P3/10; A61P5/50; A61P9/10; A61P9/12; A61P13/12; A61P17/02; A61P25/00; A61P27/02; A61P27/12; A61P43/00

Domestic Patent References:

JP2013506634A	2013-02-28
JP2013510875A	2013-03-28
JP2008517921A	2008-05-29
JP2003144528A	2003-05-20

Foreign References:

WO2009125975A2

2009-10-15

Other References:

JPN6014045850; Ｃ．　Ｊ．　Ｂａｉｌｅｙ　ｅｔ　ａｌ．: Ｄｉａｂｅｔｏｌｏｇｉａｖｏｌ．５２，　Ｎｏ．Ｓ１, 200910, ｐ．Ｓ７６
JPN6014045852; Ａ．　Ｂｏｌｄｙｓ　ｅｔ　ａｌ．: Ｐｈａｒｍａｃｏｌｏｇｉｃａｌ　Ｒｅｐｏｒｔｓｖｏｌ．６１，　Ｎｏ．５, 200910, ｐ．７７８-７８４

Attorney, Agent or Firm:

Samejima Mutsumi
Kyousei Tamura
Nagatoshi Shinagawa

Previous Patent: DERIVATIVES OF N2-(3-PYRIDYL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATME...

Next Patent: EXCELLENT CONTROL OF BLOOD GLUCOSE IN DIABETES TREATMENT